WESTLAKE-CORPORATION
11.7.2024 21:17:27 CEST | Business Wire | Press release
This year, a particularly large number of plastics converters took part in the annual polymer producers’ assessment sponsored by the Polymers for Europe Alliance. All polymers users in Europe had until mid-May to vote and rate their polymer suppliers' performance during the past 12 months. Following this year's key criteria delivery reliability, circularity, quality, communication, innovation and commitment to the European Market, Westlake Vinnolit won the PVC category with 92% of the vote. "We are delighted with this great success and would like to thank our customers for their continued trust and inspiration," said Dr. Karl-Martin Schellerer, Senior Vice President, Westlake Performance and Essential Materials - Europe and Asia, and Managing Director of Westlake Vinnolit. "At the same time, this is the greatest incentive for us to continue to improve."
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711680182/en/
‘Supplier of the year for PVC’ and ‘Overall Award – Decarbonisation’ for Westlake Vinnolit: Ron Marsh, Chairman of the Polymers for Europe Alliance (left), congratulated Dr. Karl-Martin Schellerer, Senior Vice President, Westlake Performance and Essential Materials - Europe and Asia. (Photo: Polymers for Europe Alliance)
Furthermore, Westlake Vinnolit also won the ‘Overall Award – Decarbonization.’ “The PVC Award is a major accolade, surpassed only by being awarded the number one plastics supplier in terms of decarbonization,” said Schellerer, who received the awards and certificates from Ron Marsh, Chairman of the Alliance, and EuPC President Benoît Hennaut, at the ceremony that took place at the European Plastics Converters’ conference ‘A Circular Future with Plastics’ in Brussels. “The de-fossilization of plastics is an important building block in the effort to combat climate change and one of the biggest challenges for the industry. With our CO2-saving GreenVin® product line, we actively support our customers in helping them to reduce Scope 3.1 emissions and advance their sustainability goals.”
Vinnolit GreenVin® PVC is produced entirely with electricity from renewable energy sources, backed with European high-quality certificates for renewable energies (Guarantees of Origin / HKNs) and saves around 25% CO2 equivalents in comparison to conventionally produced ®Vinnolit PVC. The respective carbon footprint was calculated by Sustainable AG in accordance with the ISO 14067 standard and certified by TÜV Rheinland. GreenVin® bio-attributed PVC, in addition, uses renewable ethylene based on 2nd generation biomass, which increases the CO2 savings to around 90%, taking into account the biogenic CO2 fixation. Vinnolit GreenVin® bio-attributed PVC is mass-balanced and certified according to ISCC PLUS and REDcert2. The favorable product and processing properties desired by customers remain unchanged.
The Polymers for Europe Alliance was initiated by the European Plastics Converters association (EuPC) to provide factual public information on the status of the polymer supply situation in Europe and to engage in a constructive dialogue with the supply base. The initiatives of the Alliance also include the Polymer Producers Awards for Europe. In this Europe-wide customers’ satisfaction survey all users of polymers in Europe can rate their suppliers of the year.
ABOUT WESTLAKE VINNOLIT
As a leading manufacturer for PVC and an important partner for caustic soda, Westlake Vinnolit offers individual solutions for customers from a wide range of industries, such as the construction sector, the automotive industry, medical technology or pulp and paper production. As a manufacturer of high-quality PVC specialties, Westlake Vinnolit is a global market leader. At its headquarters in Ismaning near Munich and its four production sites in Burghausen, Gendorf, Knapsack and Cologne, 1,400 employees generate annual sales of more than €1 billion.
Westlake Vinnolit participates in the chemical industry's Responsible Care program for the continuous improvement of safety, health and environmental protection and supports VinylPlus®, the European PVC industry's voluntary commitment to sustainable development, as an "Official Partner" financially, ideally and through active participation. For more information visit www.westlakevinnolit.com
ABOUT WESTLAKE CORPORATION (WLK)
Westlake is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the Company's web site at www.westlake.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711680182/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
